Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma

Primary bone marrow diffuse large B cell lymphoma (DLBCL) is an independent pathologic type with a poor prognosis when treated with standard chemoimmunotherapy. Generally, rituximab-based high-dose chemotherapy regimens such as dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Chen, Chen, Zehui, Li, Yueyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350052/
https://www.ncbi.nlm.nih.gov/pubmed/32643971
http://dx.doi.org/10.1177/0300060520936053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350052/
https://www.ncbi.nlm.nih.gov/pubmed/32643971
http://dx.doi.org/10.1177/0300060520936053

Ejemplares similares